Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

Video

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Patients with HER2-positive disease were treated with pertuzumab (Perjeta) plus trastuzumab (Herceptin) in addition to chemotherapy. Both drugs were given for the entire 24 weeks, and trastuzumab was continued for up to 1 year.

In the HER2-positive population, hormone receptor (HR)-negative patients had a pathological complete response (pCR) rate that was much higher than the other 2 cohorts at 75%. This pCR rate is more important in patients with HER2-positive disease than in patients with triple-negative, says Loibl.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute